tbuckley/cabot-search huggingface dataset:
Bleeding Risk and Dexamethasone Use in Children Undergoing Tonsillectomy—Reply
Authors: Thomas Q. Gallagher, Matthew T. Brigger, Christopher J. Hartnick
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics
Authors: Joyce F. Liu, Sangeetha Palakurthi, Qing Zeng, Shan Zhou, Elena Ivanova, Wei Huang, Ioannis K. Zervantonakis, Laura M. Selfors, Yiping Shen, Colin C. Pritchard, Mei Zheng, Vilmos Adleff, Eniko Papp, Huiying Piao, Marian Novak, Susan Fotheringham, Gerburg M. Wulf, Jessie English, Paul T. Kirschmeier, Victor E. Velculescu, Cloud Paweletz, Gordon B. Mills, David M. Livingston, Joan S. Brugge, Ursula A. Matulonis, Ronny Drapkin
Journal: Clinical Cancer Research (2016)

Abstract Purpose: Ovarian cancer is the leading cause of death from gynecologic malignancy in the United States, with high rates of recurrence and eventual resistance to cytotoxic chemotherapy. Model systems that allow for accurate and reproducible target discovery and validation are needed to support further drug development in this disease. Experimental Design: Clinically annotated patient-derived xenograft (PDX) models were generated from tumor cells isolated from the ascites or pleural fluid of patients undergoing clinical procedures. Models were characterized by IHC and by molecular analyses. Each PDX was luciferized to allow for reproducible in vivo assessment of intraperitoneal tumor burden by bioluminescence imaging (BLI). Plasma assays for CA125 and human LINE-1 were developed as secondary tests of in vivo disease burden. Results: Fourteen clinically annotated and molecularly characterized luciferized ovarian PDX models were generated. Luciferized PDX models retain fidelity to both the nonluciferized PDX and the original patient tumor, as demonstrated by IHC, array CGH, and targeted and whole-exome sequencing analyses. Models demonstrated diversity in specific genetic alterations and activation of PI3K signaling pathway members. Response of luciferized PDX models to standard-of-care therapy could be reproducibly monitored by BLI or plasma markers. Conclusions: We describe the establishment of a collection of 14 clinically annotated and molecularly characterized luciferized ovarian PDX models in which orthotopic tumor burden in the intraperitoneal space can be followed by standard and reproducible methods. This collection is well suited as a platform for proof-of-concept efficacy and biomarker studies and for validation of novel therapeutic strategies in ovarian cancer. Clin Cancer Res; 23(5); 1263–73. ©2016 AACR.
Use of cryobiopsy during pleuroscopy for diagnosis of sarcomatoid malignant mesothelioma
Authors: Hiang-Ping Chan, Mei-Fong Liew, Ju-Ee Seet, Pyng Lee
Journal: Thorax (2016)

A 74-year-old man presented with cough of 3 weeks' duration. Chest X-ray showed a large left-sided pleural effusion (figure 1) that was a lymphocytic exudate with normal adenosine deaminase level, and negative bacterial and mycobacterial cultures. Flexi-rigid pleuroscopy (LTF 160, Olympus, Japan) revealed candle-wax fibrotic parietal pleura (figure 2), which was sampled using the flexible forceps (FB-55CD-1, Olympus, Japan) with cusps measuring 2.4 mm when fully open, and a cryoprobe of 2.4 mm in diameter (20416-032, Erbokryo CA, Erbe, Germany). The cryoprobe was directed to the target area and 4-second freeze time was applied. The pleuroscope and cryoprobe with the pleural specimen attached …
Tissue distribution and tumor uptake of folate receptor–targeted epothilone folate conjugate, BMS-753493, in CD2F1 mice after systemic administration
Authors: Hong Shen, Lifei Wang, Weiqi Chen, Krista Menard, Yang Hong, Yuan Tian, Samuel J. Bonacorsi, W. Griffith Humphreys, Francis Y. Lee, Jinping Gan
Journal: Acta Pharmaceutica Sinica B (2016)

To assess targeting of an epothilone folate conjugate (BMS-753493) to the folate receptor (FR)-overexpressed tumor in mice bearing both FR+ and FR- tumors, a series of experiments were conducted by quantitative whole-body autoradiography (QWBA) and LC-MS/MS following i.v. administration of BMS-753493 or its active moiety, BMS-748285 in mice bearing FR+ (98M109) and FR- (M109) tumors. QWBA showed [3H]BMS-753493-derived radioactivity was extensively distributed to various tissues. The FR over-expressing 98M109 tumors showed consistently higher level of radioactivity than FR-negative tumors (i.e., M109 tumors) up to 48 h post dose of [3H]BMS-753493, despite the magnitude of difference between the tumors is relatively small (generally 3~5-fold). The radioactivity level in 98M109 tumors was 2~12-fold of normal tissues except intestine/content at 48 h post dose. No selective radioactivity uptake into 98M109 tumors over M109 or normal tissues was observed after i.v. administration of the active epothilone, [3H]BMS-748285. LC-MS/MS measurements demonstrated that the concentrations of BMS-748285, presumably from hydrolysis of the folate conjugate, in 98M109 tumors were greater than those in M109 tumors after i.v. administration of BMS-753493 (2-3-fold) whereas no differential uptake in the tumors following BMS-748285 administration. Those data were consistent with radioactivity determinations. Those results demonstrated that the folate conjugation in BMS-753493 enabled moderately preferential distribution of the active epothilone to FR over-expressing 98M109 tumors, thereby supporting targeted delivery of cytotoxics through the folate receptor.
Supermarkets criticise obesity strategy’s lack of mandatory restrictions on sugar
Authors: Gareth Iacobucci
Journal: BMJ (2016)

Major UK supermarkets have criticised the government’s watered-down strategy to tackle childhood obesity for failing to impose mandatory restrictions on the amount of sugar in food.

The long awaited plan for tackling obesity in England, published on 18 August,1 has been heavily criticised by doctors’ leaders, dentists, and campaign groups for recommending only voluntary action on sugar limits and failing to impose measures to limit advertising and “two for one” …
Anti-EGFR or Bevacizumab in first line treatment of RAS wild type metastatic colorectal neoplasm (RwtMCRC): meta-analysis of randomized clincal trials
Authors: E. Tamburini, B. Rudnas, L. Gianni, F. Drudi, S. Nicoletti, C. Santelmo, C. Ridolfi, G. Pasini, P. Fabbri, M. Papi, D. Tassinari
Journal: Annals of Oncology (2015)
Identification of GAPDH on the surface of Plasmodium sporozoites as a new candidate for targeting malaria liver invasion
Authors: Sung-Jae Cha, Min-Sik Kim, Akhilesh Pandey, Marcelo Jacobs-Lorena
Journal: The Journal of Experimental Medicine (2016)

Malaria transmission begins when an infected mosquito delivers Plasmodium sporozoites into the skin. The sporozoite subsequently enters the circulation and infects the liver by preferentially traversing Kupffer cells, a macrophage-like component of the liver sinusoidal lining. By screening a phage display library, we previously identified a peptide designated P39 that binds to CD68 on the surface of Kupffer cells and blocks sporozoite traversal. In this study, we show that the P39 peptide is a structural mimic of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) on the sporozoite surface and that GAPDH directly interacts with CD68 on the Kupffer cell surface. Importantly, an anti-P39 antibody significantly inhibits sporozoite liver invasion without cross-reacting with mammalian GAPDH. Therefore, Plasmodium-specific GAPDH epitopes may provide novel antigens for the development of a prehepatic vaccine.
Ibrutinib Differentially Interferes With Surface IgM and IgD BCR Signaling Kinetics In Chronic Lymphocytic Leukemia
Authors: Elisa ten Hacken, Cristina Scielzo, William G. Wierda, Michael J. Keating, Susan O'Brien, Paolo Ghia, Federico Caligaris-Cappio, Jan A. Burger
Journal: Blood (2013)
Integrated Somatic Mutation and DNA Methylation Analysis Reveal Genomic and Epigenomic Co-Evolution In Follicular Lymphomas
Authors: Markus Loeffler, Markus Kreuz, Andrea Haake, Dirk Hasenclever, Heiko Trautmann, Christian Arnold, Karsten Winter, Wolfram Klapper, René Scholtysik, Maciej Rosolowski, Steve Hoffmann, Ole Ammerpohl, Monika Szczepanowski, Dietrich Herrmann, Ralf Kueppers, Christiane Pott, Reiner Siebert
Journal: Blood (2013)
S11 Audit of the safety of Bronchial Thermoplasty using a national register and Hospital Episode Statistics: Abstract S11 Table 1
Authors: J Burn, AJ Sims, K Keltie, H Patrick, S Welham, RM Niven, LG Heaney
Journal: Thorax (2015)

<h3>Introduction and objectives</h3> NICE Guidance for bronchial thermoplasty (BT) recommends the collection of long term safety evidence. In this study we assess patient characteristics and safety outcomes using the British Thoracic Society (BTS) UK Difficult Asthma Registry (DAR) and the Hospital Episodes Statistics (HES) database. <h3>Methods</h3> BT patient records were extracted from DAR. HES was searched for episodes from 1<sup>st</sup> April 2011 to 31<sup>st</sup> January 2015 with OPCS-4 code combinations known to be used for BT; for these patients, inpatient and A&amp;E episodes were extracted in a second search from 1<sup>st</sup> April 2010 to 31<sup>st</sup> January 2015. DAR and HES were reviewed for complications, post-procedure stay, 30-day readmissions and A&amp;E attendances. Using anonymised matching, records from both sources were used to calculate combined safety outcomes. As BT is usually delivered in three treatments, first, second and third BT procedures were analysed separately. <h3>Results</h3> Details of 215 BT procedures (83 patients) were extracted from DAR and 203 procedure episodes (85 patients) were extracted from HES, of which 152 procedures (59 patients) matched. In comparison with three clinical trials (AIR, AIR2 and RISA), patients receiving BT in routine clinical practice were on average older, had worse baseline FEV<sub>1</sub> (except for RISA trial) and had lower AQLQ scores (Table 1). There were no significant differences in outcomes between first, second and third BT procedures; hence rates for all three procedures were combined for the matched cohort (Table 1). In the matched cohort, 27% (41/152) of procedures were associated with a complication, readmission or A&amp;E attendance. This is higher than reported hospitalisation rates for the AIR2 8.4% (16/190) and AIR trials 7.3% (4/55), and comparable with the RISA trial, 26.7% (4/15). <h3>Conclusion</h3> We present the safety of BT in routine clinical practice using combined information from a clinical register with good coverage and routine administrative data. It is likely that the clinical practice has been to treat patients with severity levels of asthma comparable to that seen in the RISA trial (high severity), compared to those used in the pivotal trial AIR2 or AIR studies, (moderate to severe), nevertheless these findings warrant further study.
Apolipoprotein synthesis in nonalcoholic steatohepatitis
Authors: Michael Charlton, Raghavakaimal Sreekumar, Deborah Rasmussen, Keith Lindor, Sreekumaran K. Nair
Journal: Hepatology (2002)

The pathophysiology of hepatic steatosis, a prerequisite of nonalcoholic fatty liver disease, is poorly understood. Because very-low-density lipoprotein (VLDL) formation is the chief route of hepatic lipid export, we hypothesized that the synthesis of apoB-100, a rate-determining step in hepatic VLDL formation, may be altered in patients with nonalcoholic steatohepatitis (NASH). This study evaluated the relative synthesis rates of apolipoprotein B-100 (apoB-100) in patients with NASH and in lean and body mass index (BMI)-matched (obese) controls without NASH. A primed continuous infusion of L-[1-(13)C] leucine was used to measure the absolute synthesis rates (ASR) of apoB-100 and fibrinogen in 7 patients with NASH and compared them with 7 lean and 7 obese (BMI-matched) controls without NASH. The ASRs of fibrinogen and albumin also were measured. The mean ASR of apoB-100 in patients with NASH was lower (31.5 +/- 3.4 mg/kg/d) than that of obese (115.2 +/- 7.2 mg/kg/d, P <.001) and lean controls (82.4 +/- 4.1 mg/kg/d, P =.002). In contrast, the mean ASR of fibrinogen was greater in subjects with NASH than in both control groups. These data indicate that NASH is associated with markedly altered hepatic synthesis of apoB-100. The finding that albumin synthesis was not similarly decreased in patients with NASH shows that the attenuation of apoB-100 synthesis is not on the basis of globally impaired hepatic protein synthesis. In conclusion, because apoB-100 synthesis is a rate-determining step in hepatocyte lipid export, decreased synthesis of this protein may be an important factor in the development of hepatic steatosis, a prerequisite for NASH.
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
Authors: Jeffrey R. Infante, Philippe A. Cassier, John F. Gerecitano, Petronella O. Witteveen, Rashmi Chugh, Vincent Ribrag, Abhijit Chakraborty, Alessandro Matano, Jason R. Dobson, Adam S. Crystal, Sudha Parasuraman, Geoffrey I. Shapiro
Journal: Clinical Cancer Research (2016)

Ribociclib (an oral, highly specific cyclin-dependent kinase 4/6 inhibitor) inhibits tumor growth in preclinical models with intact retinoblastoma protein (Rb+). This first-in-human study investigated the MTD, recommended dose for expansion (RDE), safety, preliminary activity, pharmacokinetics, and pharmacodynamics of ribociclib in patients with Rb+ advanced solid tumors or lymphomas.Patients received escalating doses of ribociclib (3-weeks-on/1-week-off or continuous). Dose escalation was guided by a Bayesian Logistic Regression Model with overdose control principle.Among 132 patients, 125 received ribociclib 3-weeks-on/1-week-off and 7 were dosed continuously. Nine dose-limiting toxicities were observed among 70 MTD/RDE evaluable patients during cycle 1, most commonly neutropenia (n = 3) and thrombocytopenia (n = 2). The MTD and RDE were established as 900 and 600 mg/day 3-weeks-on/1-week-off, respectively. Common treatment-related adverse events were (all-grade; grade 3/4) neutropenia (46%; 27%), leukopenia (43%; 17%), fatigue (45%; 2%), and nausea (42%; 2%). Asymptomatic Fridericia's corrected QT prolongation was specific to doses ≥600 mg/day (9% of patients at 600 mg/day; 33% at doses >600 mg/day). Plasma exposure increases were slightly higher than dose proportional; mean half-life at the RDE was 32.6 hours. Reduced Ki67 was observed in paired skin and tumor biopsies, consistent with ribociclib-mediated antiproliferative activity. There were 3 partial responses and 43 patients achieved a best response of stable disease; 8 patients were progression-free for >6 months.Ribociclib demonstrated an acceptable safety profile, dose-dependent plasma exposure, and preliminary signs of clinical activity. Phase I-III studies of ribociclib are under way in various indications. Clin Cancer Res; 22(23); 5696-705. ©2016 AACR.
Trial Launched to Eradicate Ebola From Semen
Authors: Anita Slomski
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TSLC (tumor suppressor in lung cancer) 1 suppresses epithelial cell scattering and tubulogenesis
Authors: Mari Masuda
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

2488 

The tumor suppressor in lung cancer 1 (TSLC1/IGSF4) encodes an immunoglobulin-like cell adhesion molecule whose cytoplasmic domain contains a protein 4.1-binding motif (protein 4.1-BM) and a PDZ-binding motif (PDZ-BM). Loss of TSLC1 expression is frequently observed in advanced cancers implying its involvement in tumor invasion and/or metastasis. Using Mardin-Darby canine kidney (MDCK) cells expressing a full-length TSLC1 or various cytoplasmic deletion mutants of TSLC1, we examined the role of TSLC1 in epithelial mesenchymal transitions (EMT) during the hepatocyte growth factor (HGF)-induced tubulogenesis and cell scattering. In a three-dimensional (3D) culture, the full-length TSLC1, which was localized to the lateral membrane of MDCK cysts, inhibited HGF-induced tubulogenesis. In contrast, the mutants lacking either the protein 4.1-BM or the PDZ-BM abolished the inhibitory effect on tubulogenesis. In addition, these mutants showed aberrant subcellular localization indicating that lateral localization is correlated with the effect of TSLC1. In a two-dimensional (2D) culture, the full-length TSLC1, but not the mutants lacking the protein 4.1-BM or the PDZ-BM, suppressed HGF-induced cell scattering. Furthermore, the cells expressing full-length TSLC1 retained E-cadherin-based cell-cell adhesion even after being treated with HGF. These cells showed prolonged activation of Rac and low activity of Rho, whereas the HGF-treated parental cells induced transient activation of Rac and sustained activation of Rho. Prolonged Rac activation caused by the expression of TSLC1 required its cytoplasmic tail. These findings, taken together, suggest that TSLC1 plays a role in suppressing induction of EMT by regulating the activation of small Rho GTPases.
A Clinical Assessment of Medis-Groups
Authors: Lisa I. lezzoni
Journal: JAMA (1988)

Interest has focused recently on measuring severity of illness, both to improve the fairness of diagnosis related group—based reimbursement and to facilitate judgments about hospital quality of care. Medis-Groups® is a prominent, proprietary severity-measurement system, recently mandated for use by all Pennsylvania hospitals. We reviewed Medis-Groups and its key clinical findings. Medis-Groups produces admission scores, from 0 through 4, indicating increasing risk of imminent organ failure. Score computation is independent of diagnosis, but many key clinical findings are disease specific and require particular diagnostic technologies. Using a database including patients 65 years of age and older from 24 hospitals, we found that fewer than 1% of patients with scores of 0 or 1 died in-hospital, compared with 60% of those with scores of 4. Questions remain about the impact of the procedural nature of many key clinical findings and the independence from diagnosis. Further study is needed to determine the utility of Medis-Groups for policy purposes. (<i>JAMA</i>1988;260:3159-3163)
Bisphosphonate Use and Femoral Fractures in Older Women—Reply
Authors: Laura Y. Park-Wyllie
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma
Authors: M.A. Dickson, M.R. Mahoney, W.D. Tap, S.P. D'Angelo, M.L. Keohan, B.A. Van Tine, M. Agulnik, L.E. Horvath, J.S. Nair, G.K. Schwartz
Journal: Annals of Oncology (2016)